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The sesquiterpene lactone Parthenolide (PN) exerted a cytotoxic effect on MDA-MB231 cells, a triple-negative breast cancer (TNBC) cell
line, but its effectiveness was scarce when employed at low doses. This represents an obstacle for a therapeutic utilization of PN. In order
to overcome this difﬁculty we associated to PN the suberoylanilide hydroxamic acid (SAHA), an histone deacetylase inhibitor. Our results
show that SAHA synergistically sensitized MDA-MB231 cells to the cytotoxic effect of PN. It is noteworthy that treatment with PN alone
stimulated the survival pathway Akt/mTOR and the consequent nuclear translocation of Nrf2, while treatment with SAHA alone induced
autophagic activity. However, when the cells were treated with SAHA/PN combination, SAHA suppressed PN effect on Akt/mTOR/Nrf2
pathway, while PN reduced the prosurvival autophagic activity of SAHA. In addition SAHA/PN combination induced GSH depletion, fall in
Dcm, release of cytochrome c, activation of caspase 3 and apoptosis. Finally we demonstrated that combined treatment maintained both
hyperacetylation of histones H3 and H4 induced by SAHA and down-regulation of DNMT1 expression induced by PN. Inhibition of the
DNA-binding activity of NF-kB, which is determined by PN, was also observed after combined treatment. In conclusion, combination of PN
to SAHA inhibits the cytoprotective responses induced by the single compounds, but does not alter the mechanisms leading to the
cytotoxic effects. Taken together our results suggest that this combination could be a candidate for TNBC therapy.
J. Cell. Physiol. 230: 1276–1289, 2015. © 2014 Wiley Periodicals, Inc.
Triple-negative breast cancer (TNBC) refers to a very
aggressive subtype of breast carcinomas associated with poor
prognosis (Dey et al., 2012). These forms of breast cancers do
not express estrogen, progesterone and HER2/neu receptors
and are unresponsive to treatment with hormonal therapy or
Herceptin (Bauer et al., 2007). Chemotherapy with
anthracyclines, taxanes, and platinum agents is the main form of
treatment, but is accompanied by a high rate of recidivism
(Bayraktar and Glück, 2013). Therefore, a novel treatment
strategy founded on the biochemical characteristics of TNBCs
is urgently needed.
Parthenolide (PN), the principal bioactive sesquiterpene
lactone component of feverfew Tanacetum parthenium, exerts
anti-tumor activity on several cancer cell types, including
prostate (Sun et al., 2010), pancreatic (Liu et al., 2010a) and
colorectal cancers (Zhang et al., 2004), multiple myeloma
(Suvannasankha et al., 2008), osteosarcoma (D’Anneo et al.,
2013a) and melanoma (D’Anneo et al., 2013a), while it shows
low toxicity in normal cells. It is noteworthy that PN is the ﬁrst
small molecule found to be active against cancer stem cells
(Ghantous et al., 2013). The anti-tumour activity of PN has
been primarily correlated with the inhibition of the NF-kB
transcription factor (Ghantous et al., 2013). PN has been
shown to prevent the DNA binding activity of NF-kB by
inhibition of IkB phosphorylation (Kwok et al., 2001).
Furthermore, it can inhibit NF-kB activity because causes the
alkylation of cysteine sulfhydryl groups in the p65 subunit
(García-Piñeres et al., 2004). In addition PNdown-regulates the
activity of DNA methyltransferase 1 (DNMT1) (Liu et al.,
2009), an enzyme involved in DNA methylation, through an
inhibition of its expression and a direct covalent binding to the
thiol groups in the catalytic site of the enzyme. This results in a
signiﬁcant DNA hypomethylation both in vitro and in vivo.
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Finally, many lines of evidence indicate that PN induces
cytotoxic effects in tumour cells by increasing the production
of reactive oxygen species (ROS) (D’Anneo et al., 2013a,b;
Zunino et al., 2007). Unfortunately, the pharmacologic use
of PN is very difﬁcult owing to its scarce solubility. In this
regard, recently a dimethylamino-analogue of PN (DMAPT)
soluble in ethanol, and its water-soluble derivative, fumarate
salt, have been generated, which improve solubility and
bioavailability and exhibit an acceptable toxicological proﬁle in
animal studies (Guzman et al., 2007). DMAPT eradicates
primary leukaemia stem cells and suppresses in vivo the
growth of prostate, lung, and bladder cancers (Shanmugam
et al., 2010, 2011).
Interestingly, it has been observed that PN and its analogues
induce in leukaemia cells a cytoprotective response that
reduces the potency of the cytotoxic action exerted by the
compounds (Sen et al., 2013). This response represents a limit
to the potential use of PN as anti-cancer drug.
We have provided evidence that PN induced a caspase-
independent cell death in MDA-MB231 cells (D’Anneo et al.,
2013b), a TNBC cell line. This effect was clearly observed at
15–25mM and was correlated with generation of ROS
(D’Anneo et al., 2013b; Carlisi et al., 2014). In addition, we have
shown that DMAPT signiﬁcantly decreased tumour growth in
mice bearing xenografts of MDA-MB231 cells, enhanced
survival of treated mice and reduced the area of lung metastasis
(D’Anneo et al., 2013b). Recently, we have performed new
research in order to evaluate compounds capable of sensitizing
MDA-MB231 cells to the cytotoxic action of PN. Preliminary
results suggest that the suberoylanilide hydroxamic acid
(SAHA), an histone deacetylase inhibitor (HDACi), is capable
of sensitizing MDA-MB231 cells to the cytotoxic effect of PN.
SAHA has been shown to induce apoptosis in a large
spectrum of haematological and solid tumors (Marks and Xu,
2009). In addition, SAHA exerts antitumor effects in a
synergistic manner with various compounds such as
topoisomerase inhibitors (Guerrant et al., 2012), proteasome
inhibitors (Emanuele et al., 2007) and TRAIL (Lauricella et al.,
2012). Furthermore, clinical investigations have provided
evidence that SAHA exhibited a high therapeutic potential for
different forms of tumors at doses that were well tolerated by
patients (Slingerland et al., 2014). Moreover, SAHA has been
approved by the “Food and Drug Administration” for therapy
in patients with haematological malignancies. Previously, we
have demonstrated that SAHA induced apoptosis in MDA-
MB231 cells (Lauricella et al., 2012). The results of the present
paper indicate that pre-treatment of MDA-MB231 cells with
SAHA sensitizes the cells to the cytotoxic effect of PN.
Materials and Methods
Chemicals and reagents
PN was supplied by Sigma-Aldrich (Milan, Italy), while SAHA was
generously provided by Italfarmaco (Milan, Italy). Stock solutions
of both compounds were prepared in dimethyl sulfoxide (DMSO)
and diluted to ﬁnal concentration in the culture medium. DMSO
employed as vehicle never exceeded 0.04% of total incubation
volume and did not show any toxic effects on MDA-MB231 cells in
comparison with the control. All reagents except for z-VAD-fmk,
which was supplied from Promega (Milan, Italy), were purchased
from Sigma-Aldrich.
Cell cultures
Breast carcinoma MDA-MB231 cells supplied from “Istituto
Scientiﬁco Tumori” (Genoa, Italy) were grown as monolayer in
Dulbecco’s Modiﬁed Eagle Medium (DMEM) supplemented with
10% fetal calf serum (FCS), 2mM glutamine and 1% non essential
amino acids, at 37°C in a humidiﬁed atmosphere containing 5%
CO2. Before each experiment, cells were seeded in 96 or 6-well
plates and were allowed to adhere overnight, then were treated
with chemicals or vehicle only.
Detection of cell death
Cell viability was ascertained by MTTmethod, a colorimetric assay
for measuring the activity of mitochondrial dehydrogenases that
reduce the tetrazolium dye, MTT, to formazan. The absorbance of
the formazan was measured directly at 490 nm in a 96-well plate,
using an automatic ELISA plate reader (OPSYS MR, Dynex
Technologies, Chantilly, VA) as previously described (D’Anneo
et al., 2013b). Apoptotic and necrotic effects were identiﬁed by
staining with ﬂuorescein isothiocyanate-conjugated (FITC)-
Annexin V and propidium iodide (PI) using a commercial kit (BD
Biosciences Pharmingen, San Diego, CA) and following the
manufacturer’s directions. Fluorescence of the cells (105 per
condition) was analysed by ﬂow cytometry on a Beckman Coulter
Epics XL ﬂow cytometer (Brea, CA) and data were analysed by
Expo32 software.
Analysis of reactive oxygen species (ROS)
The generation of intracellular reactive oxygen species (ROS) was
detected using the cell-permeant 5-(and-6)-carboxy-20,70-
dichlorodihydroﬂuorescein diacetate (H2-DCFDA, Molecular
Probe, Life Technologies, Eugene, OR), a ﬂuorogenic dye that easily
diffuses across cell membranes becoming oxidized by ROS.
Following the incubation of cells (8 103/well) with drugs for
various times, the medium was replaced with 100ml of 50mM H2-
DCFDA in HBSS (Hank’s Salt Balanced Solution) and incubation
was protracted for 30min at 37°C in the dark. Then the dye was
removed and 100ml PBS were added. After 20min the
ﬂuorescence was directly detected by means of a ﬂuorescence
microscope using a FITC ﬁlter with an excitation and an emission
wavelength of 485 nm and 530 nm, respectively. To determine the
percentage of cells producing reactive oxygen intermediates, cells
with green ﬂuorescence were counted and the values were
normalized to the total cell count/ﬁeld. At least 5 ﬁelds/condition
were analyzed.
Measurement of GSH content
The intracellular GSH level was measured using a commercial
assay provided by OXIS Research (Portland, OR). Brieﬂy, after
treatment with compounds, the cells (5 105/condition) were
collected and centrifuged at 120 g for 8min. The pellets were
resuspended in 50ml metaphosphoric acid (5 g/100ml distilled
water) and centrifuged at 3000 g for 10min. GSH content was
measured as described by manufacturer’s instructions.
Absorbance was read at 400 nm in a 96-well plate reader (OPSYS
MR, Dynex Technologies, Chantilly, VA). Intracellular GSH
content was reported as nanomoles of GSH per 105 cells.
Measurement of NF-kB activity
NF-kB activity was evaluated by an Elisa-based assay (Trans-AM
NF-kB; Active Motif, Carlsbad, CA) as described by manifacture’s
protocol. Nuclear extracts were prepared as previously reported
(D’Anneo et al., 2013a), using 3 105 cells/condition. Aliquots
were placed in 96-well plates coated with an oligonucleotide
containing the NF-kB consensus sequence. NF-kB activity was
detected using a speciﬁc antibody for p65 subunit provided by the
kit (D’Anneo et al., 2013b).
Labeling of autophagic vacuoles by
monodansylcadaverine
Following treatment with compounds, the cells (8 103/well)
were incubated with 0.05mM monodansylcadaverine (MDC) in
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PBS at 37°C for 10min in the darkness (Biederbick et al., 1995).
Then, cells were washed twice with PBS and immediately analysed
by ﬂuorescence microscopy using a Leica DMR inverted
microscope equipped with a DAPI ﬁlter system (excitation
wavelength of 372 nm and emission wavelength of 456 nm). Images
were obtained with a CCD camera and processed using the Leica
Q Fluoro Software (Wetzlar, Germany).
Western blotting analysis
Whole cell lysates were prepared as previously reported (Carlisi
et al., 2011) and protein concentration was determined by Lowry
assay (Lowry et al., 1951). As far as cytochrome c analysis,
mitochondrial and cytosolic fractions were prepared as previously
reported (D’Anneo et al., 2013a). Equal amounts of protein
samples (50mg/lane) were run in a SDS polyacrylamide gel
electrophoresis, then transferred to a nitrocellulose membrane.
All analyses were performed using speciﬁc primary antibodies
which were provided by Santa Cruz Biotechnology (Santa Cruz,
CA), except for LC-3 which was fromNovus Biologicals (Littleton,
CO), phospho-mTOR, beclin-1, phospho-p70S6K, p21, p27,
cytochrome c, and caspase 3 which were from Cell Signaling
Technology (Beverly, MA) and ULK1/2, DNMT1 and b-actin from
Sigma-Aldrich. Then the detection was developed by using a
secondary antibody conjugated with alkaline phosphatase. Protein
bands were visualized using NBT (nitroblue tetrazolium) and BCIP
(5-bromo-4-chloro-3-indoyl-phosphate) and their intensity was
quantiﬁed by densitometric analysis using SMX Image software
(BioRad, Hercules, CA). The correct protein loading was
ascertained by red Ponceau staining and immunoblotting for b-
actin. Cytochrome c oxidase (COX IV) was used as mitochondrial
control. All the blots shown are representative of at least three
separate experiments.
Analysis of mitochondrial membrane potential
The mitochondrial membrane potential in MDA-MB231 cells was
measured using the cationic dye JC-1, which in depolarized
mitochondria shows a ﬂuorescence shift from red (emission of JC-1
aggregated form at 590nm) to green (emission of JC-1 monomeric
form at 525 nm). Consequently, the dissipation of mitochondrial
membrane potential is indicated by a decrease in the red-to-green
ﬂuorescence-intensity ratio. After treatmentwith compounds, cells
(8 103/well) were incubated with medium containing JC-1
(Cayman Chemical Company, Ann Arbor, MI) for 15min at 37°C
and thenwashed twicewith PBS. Theywere then analysedon a Leica
DMR ﬂuorescence microscope (Wetzlar, Germany) by using
appropriate ﬁlters for rhodamine (excitation wavelength of 596 nm
and an emission wavelength of 620 nm) and FITC (excitation
wavelength of 485 nm and emission wavelength of 530 nm).
Cellular localization of Nrf2 in MDA-MB231 cells by
ﬂuorescence microscopy analysis
To assess the intracellular localization of Nrf2 factor, cells
(8 103/well) were subjected to indirect immunoﬂuorescence
analysis in a 96-well plate. Nuclei were visualized by staining
the cells with Hoechst 33342 dye (2.5mg/ml) for 30min, before
the treatment with the compounds. After the treatment the cells
were ﬁxed for 5min with 3% paraformaldehyde and permeabilized
with 0.1% Triton X-100 for 5min at room temperature. The
nonspeciﬁc binding sites were blocked for 1 h in PBS containing 1%
(vol/vol) BSA, after which the ﬁxed cells were incubated overnight
at 4 °C with a rabbit polyclonal primary antibody directed against
human Nrf2 (Santa Cruz, Ca) diluted 1:100 in PBS. Cells were then
washed thrice with PBS and incubated for 2 h with a FITC-
conjugated secondary antibody (Santa Cruz, Ca) diluted 1:100 in
PBS. Finally, analyses were performed by a Leica DMR
ﬂuorescence microscope equipped with a DC300F camera (Leica
Microsystems, Wetzlar, Germany). The Hoechst 33342 staining
was acquired using DAPI ﬁlter (excitation wavelength of 372 nm
and emission wavelength of 456 nm), while the Nrf2 staining was
visualized by FITC ﬁlter (excitation wavelength of 485 nm and
emission wavelength of 530 nm). Using Leica Q Fluoro Software
(Leica Microsystems), images of the DAPI and FITC ﬂuorescence
patterns were merged to visualize intracellular localization of Nrf2
protein.
Statistical analysis
Data are expressed as mean S.E. Data were analyzed using
the Student’s t-test. A P-value below 0.01 was considered
signiﬁcant.
Results
Pre-treatment with SAHA increased the cytotoxic effect
of PN
Our previous studies (D’Anneo et al., 2013b) demonstrated
that PN induced in MDA-MB231 cells a cytotoxic effect because
it strongly stimulated reactive oxygen species generation.
However, the study of the dependence of this effect on PN
concentration revealed that at low doses, lower than 10mM, the
cells were scarcely susceptible to the cytotoxic effect. In fact as
shown in Figure 1A, 5mM PNwas unable to reduce cell viability
in a signiﬁcantmanner also after 72 hof treatment. Thereforewe
performed some experiments in order to evaluate compounds
capable of increasing the cytotoxic effect induced by PN. We
demonstrated that the histone deacetylase inhibitor SAHA was
very effective in this regard. In particular, we showed that when
SAHA and PN were added contemporaneously an additive
effect on viability of MDA-MB231 cells was found. Instead, pre-
treatment for 20 h with SAHA followed by combined treatment
with PN produced a strong synergistic effect. As shown in
Figure 1B, pre-treatment of cells with 2mM SAHA for 20 h
decreased cell viability to 85% of control. Addition of 10mMPN
after pre-treatment reduced cell viability; this effect increased
with the time of the combined treatment so that after 60 h the
cell number decreased to only 3–4% of control. In order to
establish whether the treatment with the two compounds
produced a synergistic interaction, cells were treated with
various doses of SAHA and PN in a ﬁxed ratio (1:5). The effects
were compared with those determined by the single
compounds. The results reported in Figure 1C were employed
to calculate the combination indices (CI) at various values of
fraction affected (Fa) (Chou and Talalay, 1984). Figure 1D shows
that a synergistic interaction there is between SAHA and PN,
because theCI values calculated for the various values of Fawere
always inferior to 1. As shown in Figure 1E the addition of the
broad spectrum caspase inhibitor z-VAD-fmk at the start of
the pre-treatment prevented a great part of the inhibitory effect
exerted by the combined treatment on cell viability. Instead
necrostatin-1, an inhibitor of RIP-1, exerted only a modest
effect. Therefore, our results strongly suggested that the effect
on cell viability caused by the combined treatment can be
primarily considered as a consequence of the activation of
apoptosis. Finally the addition of baﬁlomycin A1 (BafA1), a
powerful inhibitorof the autophagicﬂux,markedly increased the
effect of SAHAoncell viability. In fact, SAHAreduced by 25% the
viability of cells when it was added alone and by 70% in the
presence of BafA1. This effect of BafA1 led us to the hypothesis
that SAHA exerted a role in the survival of the cells by
stimulating autophagy.
ROS generation in cells treated with SAHA and PN
The ﬂuorochrome H2-DCFDA, a general indicator of the level
of the reactive oxygen species (ROS), was chosen to ascertain
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Fig. 1. Treatment with combinations between SAHA and PN induced a strong cytotoxic effect in MDA-MB231 cells. (A) Dose and time
dependence of PN effect on cell viability. MDA-MB231 cells (8 103/well) were treated for various times with various doses of PN. At the end
cell viability was assessed by MTT assay, as reported in Materials and Methods. (B) Pre-treatment with SAHA increased PN effect on cell
viability. MDA-MB231 cells were pre-treated for 20h with 2mM SAHA. Then 10mM PN was added and the incubation was protracted for
other 20, 40, or 60h. At the end cell viability was assessed by MTT assay. (C) Comparison of the inhibitory effect on cell viability exerted by
various doses of both SAHA and PN alone with that exerted by combinations of the two compounds. Cells were treated with various doses of
SAHA (0.5–5mM) for 60h or various doses of PN (2.5–25mM) for 40h after 20h with vehicle only. For combined treatments the two
compounds were employed in a fixed ratio (1:5, SAHA:PN). After pre-treatment with SAHA for 20h, cells were treated for other 40h with
SAHA plus PN. At the end viability was assessed by MTT assay. (D) Synergistic effect between SAHA and PN on cell viability. Results shown in
Figure 1C were employed to calculate for the different percentages of the inhibitory effect (Fa, fraction affected) the corresponding values of
the combination index (CI), in accordance with Chou and Talalay (1984). Since these values were always inferior to 1 we conclude that a
synergistic interaction there is between SAHA and PN with regard to the inhibitory effect on cell viability. (E) The influence of z-VAD,
necrostatin-1 and BafA1 on the effect exerted by combined treatment with SAHA and PN on the viability of MDA-MB231 cells. Cells were
treated for 60h with the vehicle (1); for 60h with 2mM SAHA (2); for 20 h with the vehicle and then for 40h with 10mM PN (3); for 20h with
2mM SAHA and then for other 40h with SAHA and PN (4). The effectors (100mM z-VAD, 50mM necrostatin-1 and 20nM BafA1) were added
at the start of treatment. At the end viability was assessed by MTT assay. All the values are the means of three independent experiments 
S.E. *P< 0.01 compared with control.
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ROS generation by direct estimation using ﬂuorescence
microscope. We have observed (Fig. 2A and B) that after
treatment with 2mM SAHA about 80% of cells exhibited green
ﬂuorescence. Instead, treatment with 10mM PN alone caused
only a very modest production of ROS. Finally combined
treatment (SAHA/PN) produced ROS but the effect was lower
than that observed with SAHA only. Similar effects were found
for all conditions tested after 10–30h of treatment. ROS
generation was also observed in the cells prolonging the time of
the treatment until 60 h (not shown). The effect was primarily
determined by treatment with SAHA alone. Finally the addition
of apocynin and DPI, two inhibitors of NADPH oxidase
(NOX), partially prevented the effect on ROS generation
exerted by SAHA, either when it was employed alone or in
combination with PN, whatever the time of incubation was.
Because ROS generation was decreased, but not suppressed by
apocynin and DPI, we advanced the hypothesis that SAHA
could stimulate ROS generation not only through NOX
activity, but also at mitochondrial metabolic level, as shown in
leukaemia cells by Li et al. 2010.
Autophagy process in cells treated with SAHA and PN
Autophagy can be considered as the major pro-survival
mechanism, which is activated in response to many stresses,
such as starvation, hypoxia, pathogen infection and
chemotherapeutic intervention (Rubinstein and Kimchi, 2012).
Our results clearly demonstrate that SAHA strongly induced
autophagic process in MDA-MB231 cells. Staining with
monodansylcadaverine (MDC) permitted to visualize under
ﬂuorescence microscopy the presence of autophagic vacuoles
as distinct dot-like structures in the cytoplasm of treated cells.
After the treatment with 2mM SAHA, autophagic vacuoles
were clearly observed already at 10 h. Then the number of dot-
like structures progressively increased with time until 30 h of
treatment, as shown in Figure 3A. Instead, treatment with
Fig. 2. SAHA stimulated ROS generation in MDA-MB231 cells. Cells (8 103/well) were treated for the established times with 2mM SAHA
or 10mM PN alone or submitted to SAHA/PN combination after a pre-treatment with SAHA alone. The effects of apocynin (100mM) and DPI
(10mM), two inhibitors of NOX, were also ascertained. At the end, the medium was removed, 100ml of 50mMH2-DCFDA were added and the
samples were incubated for other 30min at 37°C. Then the fluorochrome was substituted with 100ml PBS and the analysis was performed
after 20min. Oxidation of the fluorochrome produced green fluorescence, which was visualized with a Leica microscope equipped with a DC
300F camera at  200 magnification using FITC filter. (A) Images of fluorescence microscopy. Scale bar 10mm. The results are representative
of three independent experiments. (B) Relative percentages of cells with green fluorescence. The values are the means of three independent
experimentsS.E. *P< 0.01 compared with vehicle treated control.
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Fig. 3. SAHA stimulated autophagic process in MDA-MB231 cells. Cells (8 103/well) were treated with various doses of SAHA or PN alone
or submitted to SAHA/PN combination after a pre-treatment with SAHA alone. (A) Detection of autophagic vacuoles with MDC test. The
effects of apocynin (100mM) and DPI (10mM) were also ascertained. At the end of treatment, the cells were incubated with 50mM MDC for
10min. Cell morphology was visualised with a Leica microscope with fluorescence filter for DAPI at  400 magnification. Scale bar 10mm.
MDC labelled autophagic vacuoles appear as distinct dot-like structures distributed in the cytoplasm. (B) Western blotting analysis showing
that treatment with SAHA or SAHA plus PN favoured conversion of LC3-I to LC3-II. The effects were increased by the addition of 20 nM
BafA1. Both in (A) and in (B) the results are representative of three independent experiments.
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10mM PN for 10–30 h was unable to stimulate the autophagic
process. Finally, SAHA/PN combination reduced the effect
observed with SAHA only.
During autophagy, the soluble form of the microtubule-
associated protein light chain 3 (LC3-I) is conjugated with
phosphatidylethanolammine producing LC3-II. This form is
stably associated with autophagosome structure. As shown in
Figure 3B, Western blotting analysis demonstrated that 2mM
SAHA favoured accumulation of LC3-II. The effect increased
with time from 10 to 30 h of treatment. In addition, our results
showed that SAHA caused a ﬂux of autophagy, as suggested by
the observation that BafA1 further increased the effect induced
by SAHA on LC3-II level.
SAHA alone and in combination with PN induced
apoptosis in MDA-MB231 cells
As reported above, autophagic process is activated in response to
stress signals. However, if the stress signal is very intense and
persistent, autophagic process cannnot ensure survival of the cells.
In this condition the mechanism of apoptosis can be triggered
leading to elimination of the cells (Rubinstein and Kimchi, 2012).
The cysteine proteases, named as caspases (Riedl and Shi, 2004),
exert a crucial role in the activation of this process. In order to
ascertain whether MDA-MB231 cells underwent apoptosis or
necrosis when they were treatedwith SAHAor PN alone or with
SAHA/PN combination, we stained the cells after the treatment
with Annexin V- ﬂuorescein isothiocyanate (FITC) and propidium
iodide (PI) and analysed by ﬂow cytometry. Figure 4A shows that
after treatment with 2mM SAHA alone for 30 h the cells
undergoing early apoptosis (Annexin V-positive/PI- negative cells,
C4) amounted to 23.4% of the total while late apoptotic cells (C2)
were equal to 11.4% and necrotic cells (C1) only to 1.5%.
Treatment with SAHA and PN increased early apoptotic cells to
33.8% and late apoptotic cells to 27.3%, while necrotic cells
remained equal to only 1.9%. Finally, these effects were prevented
by the addition of z-VAD. The results suggested that treatment
with SAHA induced apoptosis and that SAHA/PN combination
markedly increased this process. Other experiments were
performed in order to ascertain whether combined treatment
induced releaseof cytochromec anddegradationof pro-caspase 3
with the production of the active form of caspase 3 (m.w. 17 kDa)
and other cleaved forms. The results shown in Figure 4B
demonstrate that treatment with SAHA alone was unable to
induce the release of cytochromec and the activationof caspase 3.
Instead,when the cellswere treated for 20hwith 2mMSAHAand
then for other 10h with SAHA/PN combination (lane 4)
cytochrome c was released from mitochondria to cytosol.
Furthermore, the intensity of pro-caspase 3 band markedly
decreased while new bands corresponding to the active form
(m.w. 17 kDa) and to a cleaved form (12kDa) appeared. Both the
release of cytochrome c and the activation of caspase 3 were
prevented by the additionof z-VAD (lane 5).When the timeof the
treatment with combinations of SAHA and PN was prolonged to
30 h the band corresponding to pro-caspase 3 disappeared while
the intensity of the cleaved forms diminished (not shown).
Therefore, these results strongly suggested that treatment with
SAHA is capable of inducing primarily early apoptotic effects,
relating to the externalization of phosphatidylserine, while
combined treatment induces both early and late apoptosis with
the release of cytochrome c, cleavage of pro-caspase 3, and
production of the active form of caspase 3.
Mitochondrial depolarization and glutathione depletion
induced by treatment with PN and SAHA
In order to ascertain a possible role of mitochondria in the
mechanism of PN and SAHA treatment, we investigated
whether exposure to the drugs was capable of modifying
mitochondrial membrane potential (Dcm). For this analysis we
used ﬂuorescent cationic dye JC-1 and visualized ﬂuorescence
by a Leica microscope.When the cells were treated with 2mM
SAHA (20 h) or 10mM PN (10 h) alone, red orange
ﬂuorescence prevailed on greenish ﬂuorescence, suggesting
that most of cells were polarized. Instead, when the cells were
pre-treated for 20 h with SAHA and then submitted for other
10 h to combined treatment the greenish ﬂuorescence was
predominant. This was evidence that most of the cells were
depolarized as a consequence of combined treatment (Fig. 5A).
Because it has been suggested that GSH depletion can be
responsible for dissipation of Dcm (Zhang et al., 2004), we
analysed whether treatment with the drugs can induce a
decrease in the intracellular GSH level. As shown in Figure 5B,
when the cells were treated with 2mM SAHA (30 h) or 10mM
PN (10 h) alone only modest decrements in the intracellular
levels of GSH were observed. Instead, when the cells were at
ﬁrst pre-treated for 20 h with SAHA and then submitted for
other 10 h to SAHA/PN combination, the level of GSH
decreased by 56%.
Crosstalk between autophagy and apoptosis
Autophagy and apoptosis represent two distinct pathways,
which are highly interconnected through a constant crosstalk
process (Liang et al., 2012; Rubinstein and Kimchi, 2012). Many
ﬁndings today provided evidence that the cytoprotective
function of autophagy is inhibited in many cases by apoptosis,
while inhibition of autophagy can lead to the activation of
apoptosis (Liang et al., 2012). It is interesting to note that our
results suggest that SAHA, in MDA-MB231 cells, induced both
autophagy and apoptosis. This observation agrees with many
reports showing that SAHA stimulates various tumour cells in
both of these processes (Gammoh et al., 2012). In order to
study the relationships between autophagy and apoptosis, we
examined the effects of the autophagic inhibitor BafA1 on
SAHA and PN alone and on SAHA/PN combination. Our
results show that the addition of BafA1 to SAHA strongly
reduced viability of cells (Fig. 1E). Therefore, the autophagic
process induced by SAHA can be considered as a survival
mechanism. Moreover, we demonstrated by means of Annexin
V/PI test that BafA1 increased the amount of the cells found in
both C2 and C4 after treatment with SAHA (Fig. 4A),
suggesting that the inhibition of autophagy leads to the increase
of the apoptotic death. Therefore, we suggest that a cross-talk
occurs in these cells between autophagy and apoptosis.
In addition, it has been shown that some proteins which
stimulated autophagic process, such as beclin-1, are cleaved by
caspases (Gordy and He, 2012). Cleavage of beclin-1 leads to
the inhibition of the cytoprotective autophagy in cells that
became committed to apoptosis. In our experiments (Fig. 4C)
we demonstrated that the level of beclin-1 was not modiﬁed by
treatment with SAHA or PN alone, while it decreased after
treatment with SAHA/PN combination. Because this effect was
prevented by z-VAD we suggest that the apoptotic process
activated by SAHA/PN combination can lead, via caspase
activation and cleavage of beclin-1, to inhibition of autophagy. In
conclusion, with our experimental conditions autophagy seems
to be interconnected with apoptosis through mechanisms
which regulate both the processes.
Pre-treatment with SAHA suppressed the stimulatory
effect of PN on mTOR
AKT/mTOR pathway represents an important survival
mechanism that is constitutively activated in many types of
cancers (Lo Piccolo et al., 2008). Activation of the serine/
treonine kinase AKT is required for different phosphorylation
events. The other serine/treonine kinase mTOR (mammalian
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Fig. 4. SAHA alone or in combination with PN stimulated apoptosis in MDA-MB231 cells. Cells were treated for the established times with
SAHA or PN alone or submitted to a combined treatment SAHA/PN after a pre-treatment with SAHA alone. (A) Analysis by Annexin V/PI
double-staining assay. After treatment, cells were stained with Annexin V-FITC and PI and analysed by flow cytometry. C1 is related to
necrotic cells, C2 represents cells in the end stage of apoptosis or necrotic dead cells, C3 were viable cells and finally C4 represents cells
undergoing early apoptosis. Treatment with SAHA alone increased the number of cells either in early (C4) and late (C2) apoptosis. Combined
treatment with SAHA and PN further increased these effects. The effects were prevented by the addition of 100mM z-VAD, while they
increased in the presence of 20 nM BafA1. (B and C) Western blotting analysis showing the effects induced by SAHA or PN alone or in
combination on the levels of cytochrome c (B), pro-caspase 3, caspase 3, and beclin-1 (C). (B) The level of cytochrome c was evaluated both in
mitochondrial and cytosolic fractions, which were prepared as reported in Methods. Treatment with SAHA or PN alone did not produce any
effect, after treatment with SAHA/PN combination cytochrome c was detected also in the cytosolic fraction, while its level in mitochondrial
fraction diminished. (C) For these analyses changes were observed only after combined treatment. In particular caspase 3 and its cleaved
form were clearly detected, while the level of pro-caspase 3 decreased. Moreover also the level of beclin-1 markedly diminished. The addition
of z-VAD suppressed the changes observed both in (B) and in (C). All the results are representative of three independent experiments.
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target of rapamycin) is the best-studied downstream substrate
of AKT. In mammalian cells mTOR is a catalytic component of
two distinct complexes mTORC1 and mTORC2. mTORC1 is
primarily involved in the control of translation initiation and
nutrient sensing (Loewith et al., 2002). This complex is
rapamycin sensitive and induces phosphorylation of p70S6K
and 4EBP. In addition, mTORC1 inhibits autophagic process by
inducing phosphorylation of ULK1/2. In our experiments
treatment of MDA-MB231 with 10mM PN for 10 h resulted in
the phosphorylation and activation of AKT, as shown in
Figure 6A. In addition, PN induced activation of mTOR
pathway, as suggested by the remarkable increase in the level of
phospho-mTOR. This effect was accompanied by
phosphorylation of p70S6K and S6 ribosomal protein (30 kDa).
Finally, PN treatment also induced phosphorylation of ULK1/2.
Analysis was performed by using antibodies against
phosphorylated forms of AKT, mTOR, p70S6K and S6 protein.
It is noteworthy that the levels of the total proteins were not
modiﬁed by PN treatment (not shown). The presence of the
phosphorylated form of ULK1/2 was indicated by the detection
of a new band with slower mobility in SDS/PAGE. Our results
suggest that exposure to PN activates mTORC1 complex. This
conclusion is in accordance with the observations reported by
other authors for leukaemia cells (Hassane et al., 2010; Sen
et al., 2013). Treatment with SAHA alone caused modest
decrements in the levels of phosphorylated forms of AKT,
mTOR, p70S6K, S6, and ULK1/2 (Fig. 6A), but pre-treatment
with SAHA clearly inhibited the effects exerted by PN on these
forms. Therefore, SAHA prevented the activation of AKT/
mTOR pathway induced by PN.
Pre-treatment with SAHA suppressed the stimulatory
effect of PN on Nrf-2
Next, we investigated whether the cytoprotective effect
observed in the presence of low doses of PN can be mediated
by Nrf2 (Nuclear factor erythroid 2-related factor 2), a
transcription factor (Hassane et al., 2010), which is involved in
Fig. 5. Combined treatment SAHA/PN induced depolarisation in MDA-MB231 cells and caused depletion of intracellular GSH. Cells were
treated for the established times with various doses of SAHA or PN or submitted to a combined treatment after a pre-treatment with SAHA
alone. (A) Estimation of mitochondrial membrane potential (Dcm). Determinations were performed using 8 103 cells/well. After treatment
the fluorochrome JC-1 was added for additional 15min. Depolarisation was indicated by the shift of fluorescence from red-orange to greenish.
Merged images were visualized with a Leica microscope at 200  magnification with fluorescent filter for FITC and Rhodamine. Scale bar
10mm. (B) Estimation of the intracellular GSH. 5 105 cells were employed for a single sample. At the end of the treatment GSH level was
determined by using a colorimetric assay, as reported in Materials and Methods. In (A) the results are representative of three independent
experiments. In (B) the values are the means of three independent experimentsS.E. *P< 0.01 compared with vehicle treated control.
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the basal and induced expression of antioxidant enzyme genes.
In unstressed condition, Nrf2 is retained by Keap1 (Kelch-like
ECH-associated protein1) in the cytoplasm and committed to
proteosomal degradation (Kansanen et al., 2013). In contrast,
phosphorylation of Nrf2 by several cytosolic kinases (Pi et al.,
2007) stabilizes the protein, which then can translocate into the
nucleus where binds to antioxidant-response elements (AREs)
in genes encoding for antioxidative enzymes (Nguyen et al.,
2003). In accordance with other authors (Hassane et al., 2013;
Sen et al., 2013), we advanced the hypothesis that activation of
mTOR induced by PN can be responsible for phosphorylation
and translocation of Nrf2. In this regard Figure 6A shows that
treatment with PN determined the appearance of a new band
with slower mobility in SDS/PAGE, which can be identiﬁed as a
phosphorylated form of Nrf2. This band disappeared when the
cells were submitted to SAHA/PN combination. In addition we
performed an immunoﬂuorescence approach, staining with an
anti-Nrf2 antibody suitable for detection of endogenous Nrf2
(green ﬂuorescence) and with Hoechst 33342 for DNA (bleu
ﬂuorescence). As shown in Figure 7A, in MDA-MB231 cells
treated with SAHA alone Nrf2 was clearly localized in the
cytoplasm, while treatment with PN led to amarked increase of
the Nrf2 immunoﬂuorescence signal in the nuclear areas
indicating a strong translocation of Nrf2 from the cytoplasm
into the nucleus of cells. By contrast, when the cells were pre-
treated with SAHA and then exposed to PN, accumulation of
Nrf2 in the nucleus was reduced while the immunoﬂuoresce-
nce signal was primarily observed in the cytoplasm, thus
indicating that the cytoprotective action of PN was
counteracted by SAHA.
The effects of the drugs on the expression of various
factors involved in the death or in the survival of the cells
Results shown in this paper demonstrate that SAHA and PN in
combination synergistically decrease the viability of MDA-
MB231 cells. This consideration suggested to us that the two
drugs can stimulate the expression of factors involved in the
death of tumour cells or inhibit the expression of other
proteins involved in cell survival. These events could be a
consequence of epigenetic modiﬁcations. It is well known that
epigenetic changes induced by histone modiﬁcations can be
responsible for the silencing of tumour suppressor genes while
HDAC inhibitors can reactivate these genes and serve as
potential anti-cancer drugs (Marks and Xu, 2009; Slingerland
et al., 2014). Epigenetic modiﬁcations can be also a
consequence of changes in DNA methylation. In particular,
DNA methylation concerns cytosine residues in the CpG
dinucleotide sequences (Robertson, 2005). Abnormal hyper-
methylation of promoter of tumour suppressor genes has been
found in many solid tumors and blood cancers. Further it has
been shown that DNA methyl-transferases, and in particular
DNMT1, are involved in the aberrant DNA methylation
observed in cancer cells (Yoo and Jones, 2006). PN is well
known to reduce the level of DNA methylation because it
down-regulates the expression of DNMT1 and inhibits its
catalytic activity (Liu et al., 2009). Our results demonstrate that
treatment with SAHA strongly increased the acetylated forms
of histones H3 and H4. In addition, SAHA stimulated the
expression of both p21 and p27, two products of tumour
suppressor genes and attenuated the level of Bcl-2, an
antiapoptotic protein (Fig. 6B). Moreover, we show that 10mM
PN, also after brief treatments (10 h), markedly decreased the
expression of DNMT1 (Fig. 6B). In addition, treatment with PN
caused a remarkable decrement in the level of p65 and its
cleaved form as well as in the level of Bcl-2.
As shown in Figure 7B, we ascertained by Elisa assay, in
accordance with a previous ﬁnding (D’Anneo et al., 2013b),
that PN inhibited DNA-binding activity of p65, a subunit of
Fig. 6. Western blotting analyses showing changes induced by the
treatments on the expression of various factors involved in the
molecular mechanisms of the drugs. Cells (1.5 105/well) were
treated for the established times with various doses of SAHA or PN
or submitted to a combined treatment after a pre-treatment with
SAHA alone. At the end the extracts were prepared and employed
for Western blotting analyses. (A) PN stimulated the mTOR
signalling pathway. Pre-treatment with SAHA suppressed this
effect. Analysis is related to phospho-AKT (S475), phospho-mTOR
(S2448), phospho-p70S6K (T389), phospho-S6, ULK1/2 and Nrf2. (B)
Analysis is related to p21, p27, p65, Bcl-2, Ac-H3, Ac-H4, and
DNMT1. Both in (A) and (B) the results are representative of three
independent experiments.
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Fig. 7. (A) PN stimulated nuclear translocation of Nrf2. Pre treatment with SAHA suppressed this effect. MDA-MB231 cells (8 103 cells)
were treated with 2mM SAHA for 30h or with 10mM PN for 10h. In combined treatment cells were pre-treated with 2mM SAHA for 20h,
then 10mM PN was added and the incubation was protracted for another 10h. After treatment cells were subjected to immunofluorescence
analysis of Nrf2 distribution using anti-Nrf2 antibody and FITC conjugated secondary antibody (green fluorescence). Nuclei were stained with
Hoechst 33342 (blue fluorescence). The nuclear translocation of Nrf2 was shown by the merge of Nrf2 immunofluorescence and nuclear
staining. Fluorescent cells were visualized with a Leica microscope equipped with a DC300F camera at 400 magnification with fluorescent
filters for FITC and DAPI for Nrf2 and Hoechst, respectively. Scale bar 10mm. (B) PN down-regulated DNA-binding activity of p65. Cells
(3 105/condition) were treated with the drugs, as reported in the legend of Figure 7A. The binding was quantified in nuclear extracts by an
Elisa assay as reported in Materials and Methods. The effect of PN was not modified by combination with SAHA. In (A) the results are
representative of three independent experiments. In (B) the values are the means of three independent experiments  S.E. *P< 0.01
compared with vehicle treated control.
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NF-kB. Treatment with 2mM SAHA did not modify this activity
while treatment with SAHA/PN combination inhibited DNA-
binding similarly to PN alone.
In conclusion, treatment with the SAHA/PN combination
induced both the hyperacetylation of histones H3 and H4 and
the down-regulation of DNMT1 (Fig. 6B). These epigenetic
effects were accompanied by the increased expression of the
tumour suppressor genes p21 and p27 and by the remarkable
decrements in the level of the survival factors Bcl-2 and p65.
Discussion
This study shows that pre-treatment with SAHA strongly
increased the cytotoxic effect exerted by PN on viability of
MDA-MB231 cells. We provided evidence that a synergistic
interaction occurred between SAHA and PN in order to their
antitumor action on these cells. The aim of our study was to
ascertain the molecular basis of this synergistic effect.
Therefore, several aspects of the problem were investigated
comparing the effects exerted by PN or SAHA alone to those
determined by SAHA/PN combination.
It is well known that both PN and SAHA are capable of
inducing epigenetic modiﬁcations. PN has been reported
(Liu et al., 2009) to inhibit in leukaemia cells DNMT1 through
alkylation of cysteine 1226 of the catalytic domain and down-
regulation of its expression. These two effects lead to global
DNA hypomethylation, which can be effective in modulating
the expression of genes involved in the stimulation of apoptotic
effects in tumour cells. Our results show that exposure to PN
decreased the expression of DNMT1. In addition, PN also
decreased the levels of both p65 protein, a component of NF-
kB, and Bcl-2 (Wyre˛bska et al., 2013), a fundamental anti-
apoptotic factor.
On the other hand we demonstrated that treatment with
SAHA induced acetylation of histones H3 and H4. These results
agree with the ﬁndings of other authors (Mitsiades et al., 2004;
Chen et al., 2013), showing that inhibitors of HDAC increased
acetylation of lysine residues in the NH2-terminal tails of
histones H3 and H4 with the consequent reactivation of the
expression of some silenced genes. Acetylation neutralizes the
positive charge of histone tails. Consequently, histone afﬁnity to
negative charged DNA diminishes, changes of nucleosome
conformation occur and DNA becomes more accessible to
transcription factors. In conclusion, histone acetylation can be
associatedwith transcriptionally active regions of the genome. In
addition, our results established that histone hyperacetylation
inducedbySAHA is associatedwithup-regulationof p21andp27
as well as with decrement of Bcl-2. These results are also in
agreement with previous ﬁndings of Bali et al. (2005).
It is noteworthy that treatment with SAHA/PN combination
led to the appearance of the modiﬁcations induced by both the
drugs. Therefore, the cells contemporaneously exhibited both
hyperacetylation of histones and decrement of DNMT1 level.
These events induce a relatively open structure of chromatin,
which can be responsible for epigenetic modiﬁcations,
favouring changes in the expression of many factors. In
particular, we observed that combined treatment was
associated with both the increased expression of the tumour
suppressor factors p21 and p27 and the decrement in the levels
of fundamental survival proteins p65 and Bcl-2. Therefore, we
advanced the hypothesis that epigenetic events can be
responsible for the changes in the expression of these proteins.
It is well known that NF-kB plays a prominent role in gene
expression in tumor cells, favouring survival and metastasis
(Baldwin, 2001). Therefore, the antitumor action of PN has
been correlated inmany tumor cells (Kwok et al., 2001; García-
Piñeres et al., 2004) with its inhibitory effect exerted on NF-kB
activity. Our results show that PN not only decreased the level
of p65, but also inhibited the DNA-binding activity of this
protein. It is noteworthy that this remarkable inhibitory effect
was not prevent by SAHA when the cells were submitted to
SAHA/PN combination.
The experiments concerning the production of ROS and the
autophagic process revealed that SAHA alone stimulated both
the processes also at low concentrations. Since apocynin and
DPI, which are two inhibitors of NOX, reduced both ROS
generation and autophagy, we suggest that SAHA primarily
stimulated NOX increasing production of ROS, which
determined activation of autophagic process. Our results are in
agreement with previous reports of other authors, showing
that SAHA strongly induces autophagic process in tumour cells
(Gammoh et al., 2012).
It is interesting to note that PN at low concentrations (5–
8mM) was unable to stimulate both the production of ROS and
the autophagic process, differently from the effect previously
observed by us at higher concentration (12–25mM). Moreover,
when PNwas added to SAHA partially reduced both the effects
of this compound on ROS generation and autophagy, while a
remarkable activation of apoptosis was observed. In order to
explain the mechanism through which PN potentiated
apoptosis induced by SAHA, we evaluated the effect of the
drugs on mitochondrial membrane potential. When the cells
were submitted to combined treatment, a remarkable fall of
Dcm was observed accompanied by a reduction of the
intracellular level of GSH. This compound, as shown by Zhang
et al. (2004), plays an important role in the stability of
mitochondrial membrane potential. Thus, a decrease in the
GSH level can be responsible for mitochondrial membrane
transition and the consequent fall of Dcm. It is interesting to
note that the fall of Dcm and the decrement of GSH level were
observed only when the cells were submitted to combined
treatment, but not when they were treated with PN or SAHA
alone. However, the mechanism through which combined
treatment decreased GSH level is unclear at this moment. Two
different modalities can be hypothesized in this regard:
oxidation of GSH and conjugation of GSH with PN. Oxidation
via ROS generation could be determined at the employed
concentrations only by SAHA, while PN was unable to
stimulate ROS production and did not increase the effect of
SAHA. Conjugation of PN with GSH can occur through its
a-methylene-g-lactone group, but SAHA does not play a role
in this regard. Therefore, we believe that both the mechanisms
can be involved in the depletion of GSH level. Our results lead
us to the conclusion that combined treatment caused fall of
Dcm in correlation with the depletion of GSH. These events
together with the activation of the products of the
oncosuppressor genes p21 and p27 and the decrements of the
levels of the survival proteins p65 and Bcl-2 can be responsible
for mitochondrial dysfunction, release of cytochrome c and
activation of caspase 3.
Finally, our results show that SAHA/PN combination also
induced a decrement of the level of beclin-1, a protein involved
in autophagosome formation. It has been shown that beclin-1
is cleaved by caspases (Gordy and He, 2012) and that its
N-terminal cleavage fragment can inhibit autophagy while the
C-terminal fragment promotes the release of cytochrome c
from mitochondria (Wirawan et al., 2010). Thus, it is possible
to hypothesize that activation of caspase 3 by SAHA/PN
treatment can be responsible for degradation of beclin-1 and
that this event can favour the inhibition of the autophagic
process activated by SAHA and the release of cytochrome c.
Recently it has been shown that treatment of acute myeloid
leukaemia cells with DMAPT induces a cytoprotective
response that can decrease the efﬁcacy of this compound. In
addition, evidence shows that this cytoprotective effect can be
a consequence of activation of the AKT/mTOR pathway in
response to PN. This ﬁnding suggested that association of PN
with compounds capable of inhibiting mTOR pathway can
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represent a useful new strategy to impair cytoprotective
activity of PN and enhance its antitumor efﬁcacy. Thus, it has
been reported that wortmannin (Hassane et al., 2010), an
inhibitor of PI3K, as well as some inhibitors of mTOR, such
as rapamycin and temsirolimus (Hassane et al., 2010) or
the antifungal drug ciclopirox (Sen et al., 2013) enhanced
the antileukemic effect of PN by impairing its cytoprotective
activity. In a previous paper (D’Anneo et al., 2013b) we have
demonstrated that PN induces a decrement of viability of
MDA-MB231 cells, which was primarily a consequence of ROS
generation. This effect was very modest at a concentration of
PN lower than 10mM. That represented a great limitation for
an effective utilization of PN and led us to hypothesize that PN
exerts a cytoprotective effect in MDA-MB231 cells by
stimulating mTOR pathway and that this protective effect
prevails at lower doses of PN, when the drug is unable to
stimulate ROS generation. Our results clearly demonstrate
that PN is an effective activator of AKT/mTOR pathway
inducing its downstream effectors p70S6K and consequently
the ribosomal protein S6. Further, when activated by PN,
mTOR directly phosphorylates ULK1/2 to inhibit the
autophagy function of the ULK complex. The observation that
SAHA strongly synergized with PN suggested to us that SAHA
can inhibit the activating effect exerted by PN on mTOR. The
hypothesis was also supported by the consideration that SAHA
is well known to inhibit AKT and mTOR in embryonic
ﬁbroblast cells (Gammoh et al., 2012) and in many tumour cells
(Hrzenjak et al., 2012; Liu et al., 2010b). Our results, showing
that SAHA when employed in combination reduced the effects
exerted by PN on mTOR pathway, suggested to us the
conclusion that SAHA behaves as an effective inhibitor of
mTOR activation.
In addition, our paper shows that PN caused nuclear
accumulation of Nrf2, a transcription factor which acts as a key
regulator of antioxidant-responsive genes. Treatment with PN
stimulated the production of a phosphorylated form of Nrf2,
which accumulated in the nucleus. Interestingly, when the cells
were submitted to combined treatment, SAHA prevented the
effect of PN and the phosphorylated form of Nrf2 was not
observed. Therefore, we conclude that PN activated the
mTOR pathway and this resulted in the phosphorylation of
Nrf2, while SAHA inhibitedmTOR activation and consequently
Nrf2 phosphorylation.
In conclusion, association between SAHA and PN exhibits
several effects concerning viability of MDA-MB231 cells: (i)
SAHA and PN together are responsible for epigenetic events
which reduced cell viability; (ii) PN inhibits SAHA effect on
autophagy; and (iii) SAHA does not modify the inhibitory effect
induced by PN onNF-kB, but does suppress the cytoprotective
effect of PN by inhibiting AKT/mTOR pathway.
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